Unlike many cancers that originate from gain-of-function mutations in OGs such as EGFR and RAS, ccRCC manifests with prevalent loss-of-function mutations in TSGs, making the development of predictive biomarkers for individual targeted therapies and/or immunotherapies extremely challenging. This evidence concerns the gene EGFR and cancer.